Discngine Labs: Predicting Antibody Developability
In silico & In vitro synergies
Therapeutic antibodies have become one of the fastest-growing drug classes in clinics. However, despite major advances in discovery processes and technologies, their successful development is often hindered by developability challenges in design and production. Therefore, methods that predict and prevent the possibility of antibody candidate failure at a later stage of development are very beneficial.
The fifth Discngine Labs will provide insights on how to successfully develop therapeutic antibodies using a combination of in silico and in vitro approaches. In the roundtable, the experts from pharma R&D will discuss their strategies for combining these two methodologies, which lead them to improved predictions and increased efficiency in antibody development.
The event will cover:
Antibody interaction predictions
De Novo design
In-vitro methods
Hear from our speakers…
Event chair:
Thierry Wurch
SVP Integrated Biologics Discovery
Evotec
Panelists:
Eric Chabrol
Project Manager
MImAbs
Andrew Henry
Principal Scientist
Chemical Computing Group
Thomas Bourquard
Co-Founder and CSO
MAbSilico
What is the Discngine Labs?
Discngine Labs is our new exciting networking event to connect Discngine customers, partners, and everyone interested in innovative solutions for research-driven organizations!
Join us at our interactive virtual venue to network and exchange (almost as in real life)!
A unique virtual experience
We will welcome you on Gather, a new virtual space!
The platform will allow you to walk around the conference space, run into peers and interact with people like you would in real life.
We tried it and we are certain this platform will help us create a unique experience for you to enjoy!